Stockholm — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments in areas of high unmet medical need, announced today that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its selective cathepsin K inhibitor MIV-711 for the treatment of Osteogenesis Imperfecta (OI). MIV-711 already holds Orphan Drug Designation (ODD) in OI, as well as ODD and RPDD in Perthes disease. The decision strengthens MIV-711 ahead of the planned proof-of-concept study in OI and, upon a future approval, MIV-711 may also qualify for a Priority Review Voucher – a transferable asset that has sold for USD 180–210 million per voucher in 2026.
MIV-711 targets the underlying bone fragility
MIV-711 inhibits cathepsin K, the main enzyme used by osteoclasts to degrade collagen in bone tissue. By reducing excessive bone resorption, MIV-711 aims to restore the balance between bone resorption and bone formation, thereby preventing fractures and skeletal deformities.
For RPDD, the FDA requires a scientific rationale and supportive data suggesting that the drug may be effective in the disease. In an OI-specific animal model, MIV-711 has shown significant and dose-dependent improvements in bone strength, bone quality and bone morphology, and clinical data in osteoarthritis support MIV-711’s ability to counteract bone degradation in humans. In its decision, the FDA concluded that OI meets the criteria for a rare pediatric disease, citing, among other things, high bone fragility with susceptibility to fracture, skeletal deformities, respiratory complications, pain and short stature.
There is currently no approved treatment that addresses the underlying bone fragility in Osteogenesis Imperfecta, and Medivir estimates the market potential for such a treatment at a minimum of USD 2.5 billion.
Priority Review Voucher – a potentially valuable asset
With RPDD, the FDA may grant Medivir a Priority Review Voucher (PRV) upon marketing approval of MIV-711 in OI. The voucher provides priority review of a subsequent marketing application and can be sold on to other companies. Transactions completed in 2026 have been concluded at between USD 180 million and USD 210 million per voucher. The PRV program has been extended several times since its introduction in 2012, most recently in February 2026, and currently runs until September 30, 2029.
For additional information, please contact:
Jens Lindberg, CEO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: jens.lindberg@medivir.com